Dr. Tobias Pöhlmann

Funktionen

• Geschäftsführer Bianoscience GmbH

Forschungsgebiete

• Development of therapeutic prodrug-nucleotides to treat mammary cancer as well as viral infections

Publikationen (ausgewählte 5 aktuelle)

1. Cell-specific RNA interference by peptide-inhibited-peptidase-activated siRNAs. Koehn S, Schaefer HW, Ludwig M, Haag N, Schubert US, Seyfarth L, Imhof D, Markert UR, Poehlmann TG. J RNAi Gene Silencing. 2010 Dec 31;6(2):422-30.
2. Progesterone-induced blocking factor activates STAT6 via binding to a novel IL-4 receptor. Kozma N, Halasz M, Polgar B, Poehlmann TG, Markert UR, Palkovics T, Keszei M, Par G, Kiss K, Szeberenyi J, Grama L, Szekeres-Bartho J. J Immunol. 2006 Jan 15;176(2):819-26.
3. Multifunctional Poly(2-oxazoline) Nanoparticles for Biological Applications. Kempe K, Vollrath A, Schaefer HW, Poehlmann TG, Biskup C, Hoogenboom R, Hornig S, Schubert US. Macromol Rapid Commun. 2010 Nov 1;31(21):1869-73. doi: 10.1002/marc.201000283.
4. Role of regulatory and angiogenic cytokines in invasion of trophoblastic cells. Dubinsky V, Poehlmann TG, Suman P, Gentile T, Markert UR, Gutierrez G. Am J Reprod Immunol. 2010 Mar 1;63(3):193-9. Epub 2009 Dec 29.
5. Assessment of caspase-4 released free AFC by RP-HPLC and fluorescence detection. Koehn S, Trueck M, Poehlmann TG, Schleussner E, Markert UR, Seyfarth L. J Chromatogr B Analyt Technol Biomed Life Sci. 2008 Oct 15;874(1-2):111-4.